Clinical Trial Update: Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma [Phase 2]

View source ↗

Summary

Phase II study of MEDI4736 (durvalumab) alone or with tremelimumab in metastatic pancreatic ductal adenocarcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• MEDI4736 (Durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2018-08-02